The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

Jun 18, 2020

During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE about the REACH2 clinical trial. REACH 2 is a phase III study evaluating ruxolitinib vs best available therapy in patients with corticosteroid-refractory acute GvHD following allogeneic stem cell transplantation.

We asked: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?

REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?